A novel dual targeted antibacterial agent for Helicobacter pylori

[...]due to overprescription of antibiotics, primary antibiotic resistance in H pylori is rising, leading to successful treatment rates declining annually.5 Rifasutenizol was the first antibiotic developed specifically for H pylori, and it exerts its antibacterial activity by inhibiting bacterial RN...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet infectious diseases 2024-06, Vol.24 (6), p.569-570
Main Authors: Chen, Jinnan, Lu, Hong
Format: Article
Language:English
Subjects:
Antibacterial activity
Antibacterial agents
Antibiotic resistance
Antibiotics
Antiinfectives and antibacterials
Asymptomatic
DNA-directed RNA polymerase
Drug dosages
Drug resistance
Helicobacter pylori
Infections
Intermediates
Nitroreductase
Pharmacokinetics
RNA polymerase
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]due to overprescription of antibiotics, primary antibiotic resistance in H pylori is rising, leading to successful treatment rates declining annually.5 Rifasutenizol was the first antibiotic developed specifically for H pylori, and it exerts its antibacterial activity by inhibiting bacterial RNA polymerase and generating highly reactive intermediates by the action of nitroreductase. According to Li and colleagues, single doses of rifasutenizol, ranging from 50 mg to 1000 mg, and multiple doses of rifasutenizol, ranging from 200 mg to 600 mg twice daily, were found to be safe and well-tolerated with no deaths or serious adverse events reported in any of the studies. [...]there are concerns regarding the dose selection for each group in trials 3 and 4.
ISSN:1473-3099
1474-4457
DOI:10.1016/S1473-3099(24)00063-X